Literature DB >> 25977330

Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions.

Saori Fujita-Sato1, Jacqueline Galeas2, Morgan Truitt2, Cameron Pitt2, Anatoly Urisman3, Sourav Bandyopadhyay2, Davide Ruggero2, Frank McCormick4.   

Abstract

Oncogenic K-Ras mutation occurs frequently in several types of cancers, including pancreatic and lung cancers. Tumors with K-Ras mutation are resistant to chemotherapeutic drugs as well as molecular targeting agents. Although numerous approaches are ongoing to find effective ways to treat these tumors, there are still no effective therapies for K-Ras mutant cancer patients. Here we report that K-Ras mutant cancers are more dependent on K-Ras in anchorage-independent culture conditions than in monolayer culture conditions. In seeking to determine mechanisms that contribute to the K-Ras dependency in anchorage-independent culture conditions, we discovered the involvement of Met in K-Ras-dependent, anchorage-independent cell growth. The Met signaling pathway is enhanced and plays an indispensable role in anchorage-independent growth even in cells in which Met is not amplified. Indeed, Met expression is elevated under anchorage-independent growth conditions and is regulated by K-Ras in a MAPK/ERK kinase (MEK)-dependent manner. Remarkably, in spite of a global downregulation of mRNA translation during anchorage-independent growth, we find that Met mRNA translation is specifically enhanced under these conditions. Importantly, ectopic expression of an active Met mutant rescues K-Ras ablation-derived growth suppression, indicating that K-Ras-mediated Met expression drives "K-Ras addiction" in anchorage-independent conditions. Our results indicate that enhanced Met expression and signaling is essential for anchorage-independent growth of K-Ras mutant cancer cells and suggests that pharmacological inhibitors of Met could be effective for K-Ras mutant tumor patients. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25977330      PMCID: PMC4506276          DOI: 10.1158/0008-5472.CAN-14-1623

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  A conserved HEAT domain within eIF4G directs assembly of the translation initiation machinery.

Authors:  J Marcotrigiano; I B Lomakin; N Sonenberg; T V Pestova; C U Hellen; S K Burley
Journal:  Mol Cell       Date:  2001-01       Impact factor: 17.970

2.  Increase in cap- and IRES-dependent protein synthesis by overproduction of translation initiation factor eIF4G.

Authors:  S Hayashi; K Nishimura; T Fukuchi-Shimogori; K Kashiwagi; K Igarashi
Journal:  Biochem Biophys Res Commun       Date:  2000-10-14       Impact factor: 3.575

3.  Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.

Authors:  E J Bernhard; E J Stanbridge; S Gupta; A K Gupta; D Soto; V J Bakanauskas; G J Cerniglia; R J Muschel; W G McKenna
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

4.  Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.

Authors:  Yikun Li; Songqing Fan; Junghui Koo; Ping Yue; Zhuo Georgia Chen; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2012-03-01       Impact factor: 4.742

5.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

6.  The soy isoflavone equol may increase cancer malignancy via up-regulation of eukaryotic protein synthesis initiation factor eIF4G.

Authors:  Columba de la Parra; Elisa Otero-Franqui; Michelle Martinez-Montemayor; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

7.  Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Authors:  Ryohei Katayama; Aki Aoyama; Takao Yamori; Jie Qi; Tomoko Oh-hara; Youngchul Song; Jeffrey A Engelman; Naoya Fujita
Journal:  Cancer Res       Date:  2013-04-18       Impact factor: 12.701

Review 8.  Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  Daquan Meng; Mingli Yuan; Xiaojuan Li; Lijun Chen; Jie Yang; Xin Zhao; Wanli Ma; Jianbao Xin
Journal:  Lung Cancer       Date:  2013-04-19       Impact factor: 5.705

Review 9.  MET: a promising anticancer therapeutic target.

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2012-05-08       Impact factor: 66.675

10.  K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Authors:  Irmgard Hofmann; Andreas Weiss; Gaelle Elain; Maria Schwaederle; Dario Sterker; Vincent Romanet; Tobias Schmelzle; Albert Lai; Saskia M Brachmann; Mohamed Bentires-Alj; Thomas M Roberts; William R Sellers; Francesco Hofmann; Sauveur-Michel Maira
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more
  26 in total

Review 1.  The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.

Authors:  Akinori Kawakami; David E Fisher
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

2.  An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.

Authors:  Martin Indarte; Roisin Puentes; Marco Maruggi; Nathan T Ihle; Geoffrey Grandjean; Michael Scott; Zamal Ahmed; Emmanuelle J Meuillet; Shuxing Zang; Robert Lemos; Lei Du-Cuny; Fabiana I A L Layng; Ricardo G Correa; Laurie A Bankston; Robert C Liddington; Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2019-04-30       Impact factor: 12.701

3.  Differential Effector Engagement by Oncogenic KRAS.

Authors:  Tina L Yuan; Arnaud Amzallag; Rachel Bagni; Ming Yi; Shervin Afghani; William Burgan; Nicole Fer; Leslie A Strathern; Katie Powell; Brian Smith; Andrew M Waters; David Drubin; Ty Thomson; Rosy Liao; Patricia Greninger; Giovanna T Stein; Ellen Murchie; Eliane Cortez; Regina K Egan; Lauren Procter; Matthew Bess; Kwong Tai Cheng; Chih-Shia Lee; Liam Changwoo Lee; Christof Fellmann; Robert Stephens; Ji Luo; Scott W Lowe; Cyril H Benes; Frank McCormick
Journal:  Cell Rep       Date:  2018-02-13       Impact factor: 9.423

4.  KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

Authors:  Dwight H Owen; Bhavana Konda; Jennifer Sipos; Tom Liu; Amy Webb; Matthew D Ringel; Cynthia D Timmers; Manisha H Shah
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

5.  Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

Authors:  Meng Wang; Jing Han; Lynnette Marcar; Josh Black; Qi Liu; Xiangyong Li; Kshithija Nagulapalli; Lecia V Sequist; Raymond H Mak; Cyril H Benes; Theodore S Hong; Kristin Gurtner; Mechthild Krause; Michael Baumann; Jing X Kang; Johnathan R Whetstine; Henning Willers
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 12.701

6.  Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.

Authors:  Kevin J Church; Brett R Vanderwerff; Rachelle R Riggers; Beatriz Mateo-Victoriano; Matthew Fagnan; Phillip H Harris; Jewel C LeValley; Joseph W Harding
Journal:  Anticancer Drugs       Date:  2018-04       Impact factor: 2.248

7.  Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.

Authors:  Erin Sheffels; Nancy E Sealover; Chenyue Wang; Do Hyung Kim; Isabella A Vazirani; Elizabeth Lee; Elizabeth M Terrell; Deborah K Morrison; Ji Luo; Robert L Kortum
Journal:  Sci Signal       Date:  2018-09-04       Impact factor: 8.192

8.  Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.

Authors:  Kevin J Church; Brett R Vanderwerff; Rachelle R Riggers; Michelle D McMicheal; Beatriz Mateo-Victoriano; Sudharsan R Sukumar; Joseph W Harding
Journal:  Anticancer Drugs       Date:  2016-09       Impact factor: 2.248

9.  KRASG12C inhibition produces a driver-limited state revealing collateral dependencies.

Authors:  Kevin Lou; Veronica Steri; Alex Y Ge; Y Christina Hwang; Christopher H Yogodzinski; Arielle R Shkedi; Alex L M Choi; Dominique C Mitchell; Danielle L Swaney; Byron Hann; John D Gordan; Kevan M Shokat; Luke A Gilbert
Journal:  Sci Signal       Date:  2019-05-28       Impact factor: 8.192

Review 10.  The Role of Wild-Type RAS in Oncogenic RAS Transformation.

Authors:  Erin Sheffels; Robert L Kortum
Journal:  Genes (Basel)       Date:  2021-04-28       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.